Sanofi fined for smear campaign against generic Plavix
This article was originally published in Scrip
Executive Summary
Sanofi has been fined €40.6 million by the French competition authority for abusing a dominant market position to run a smear campaign against generic versions of its blockbuster antithrombotic Plavix (clopidogrel).
You may also be interested in...
French Competition Body Fines Janssen €25m For Delaying Generic Durogesic
Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.
French Competition Body Fines Janssen €25m For Delaying Generic Durogesic
Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.